Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 3, 2008, Pages 248-250

  Binitha, M ^a,c   Nandakumar, G ^a   Thomas, Daisy ^b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b Department of Surgery   (India)

^c Haritha   (India)

Author keywords

Cardiac toxicity; Intravenous immunoglobulin; Scleromyxedema

Indexed keywords

ALPHA INTERFERON; BETAMETHASONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIMETHYL SULFOXIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISOLONE; RETINOID; THALIDOMIDE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CARDIOTOXICITY; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DISEASE PREDISPOSITION; ECG ABNORMALITY; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; RISK FACTOR; SCLEROMYXEDEMA; SKIN BIOPSY; SKIN DISEASE; SUDDEN DEATH; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 46349104014     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.41372     Document Type: Article

References (10)

1. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus and scleromyxedema. J Am Acad Dermatol 2001;44:273-81.
2. Martins GA, Abdala WG, de Andrade DV. Scleromyxedema with associated cardiomyopathy. Anais Brasileiras de Dermatologica 2004;79:561-6.
3. Morris-Jones R, Staughton RCD, Walker M, Sheridan DJ, Rajappan K, Leonard J, et al. Lichen myxedematosus with associated cardiac abnormalities. Br J Dermatol 2001;144:594-6.
4. Harper RA, Rispler J. Lichen myxedematosus serum stimulating human skin fibroblast proliferation. Science 1978;199:545-7.
5. Dirneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995;33:37-43.
6. Wetter DA, Dennis M, Davis P, Yiannias JA, Gibson LE, Dahl MV, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of Mayo clinic experience. Mayo Clin Proc 2005;80:41-7.
7. Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, et al. Scleromyxedema: Response to high-dose intravenous immunoglobulin (Hd IVIg). J Am Acad Dermatol 2000;43:403-8.
8. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: Properties, mode of action and practical use in dermatology. Acta Dermatol Venereol 2007;87:206-18.
9. Wojas-Pele A, Blaszczyk M, Glinska M, Jablonska S. Tumorous variant of scleromyxedema. Sucessful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2005;19:462-5.
10. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 2004;29:317-8.